DOI: 10.36347/sjams.2022.v10i06.010

Pages: 917-925

Liver cancer is the seventh most commonly occurring cancer and second commonest cancer in terms of mortality. Hepatocellular carcinoma (HCC) is the dominant type of liver cancer (Almost 75% of all liver cancers). In 2017, diabetes was the ninth cause of mortality and seventh leading cause of human suffering from disability-adjusted life years. In the five countries of the world, that report highest number of HCC cases (China, Japan, United States, India, Vietnam), the population attributable fraction of diabetes for hepatocellular carcinoma varies between 4.7% to 7.6% in men and 4.6%-7.1% in women. Though an association has been hypothesized between HCC and diabetes, the underlying mechanism is poorly understood with various theories of pathophysiology having been proposed. Moreover, there are other etiological factors that influence carcinogenesis in diabetes patients. Several risk score systems help in predicting liver cancer in diabetic population. Also, anti-diabetic agents are known to play a role in the development of liver cancer. This article aims to summarize the association of HCC and diabetes, pathophysiology of the association, influence of risk factors in development of HCC in diabetes patients, the risk scores used for prediction of liver cancer in diabetes patients, and role of anti-diabetic agents in HCC.